This article is more than 5 years old. Information may no longer be current.

Bevacizumab shows efficacy against CNV associated with pseudoxanthoma elasticum

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal bevacizumab appears effective both functionally and morphologically for treating patients with choroidal neovascularization secondary to pseudoxanthoma elasticum, a study by researchers in Germany found.

"Best recovery can be achieved in eyes with disease that has not progressed too far and if treatment is initiated at the earliest point possible," the authors said.

Robert P. Finger, MD, and colleagues at University of Bonn and Hospital Saarbrücken evaluated outcomes for 16 eyes of 15 patients treated with 1.5-mg intravitreal injections of Avastin (bevacizumab, Genentech). All patients had active CNV secondary to pseudoxanthoma elasticum.

Patients received additional injections based on disease activity, such as a vision loss of five letters or one line, persistent leakage or persistent macular edema. They received an average of 2.4 injections, according to the study.

Patients averaged 53 years of age, and follow-up averaged 8 months.

Best corrected visual acuity averaged 20/100 at baseline. After the first injection, BCVA improved to average 20/63 and remained stable through final follow-up.

Central retinal thickness significantly decreased, from 252 µm at baseline to 214 µm at final follow-up, the investigators reported.

They found that patients who had only mild morphological changes in the central macula had a significantly better improvement than patients who had evident morphological changes in the central macula, according to the study, published in the April issue of British Journal of Ophthalmology.